君聖泰醫藥完成配股,集資逾1.2億港元
君聖泰醫藥-B(2511.HK)發佈公告稱,配售的所有條件已獲達成,且配售已於2025年7月7日根據配售協議的條款完成。據悉,此次超過六名獨立承配人均爲長期戰略投資人,對公司的經營前景與未來發展有足夠的信心,並秉持長期投資理念。此次配股進一步優化了股東結構,爲公司的長期穩定發展奠定了堅實的資本基礎。公司擬將配售所得款項淨額用於集團管線產品熊去氧膽小檗鹼(HTD1801)的臨牀開發及商業化。HTD1801是本公司自主研發、首創的靶向腸-肝系統的抗炎及代謝調節劑。據悉,君聖泰醫藥自主研發的腸肝抗炎及代謝調節劑熊去氧膽小檗鹼(HTD1801)在中國2型糖尿病(T2DM)患者中開展的兩項3期臨牀試驗(SYMPHONY 1和SYMPHONY 2)成功達到主要療效終點。基於積極的臨牀試驗數據,公司計劃於今年內向國家藥品監督管理局遞交新藥上市申請。此外,HTD1801在次要療效終點方面也取得積極成果,該藥物改善胰島素抵抗,展現出糖脂同降能力,可顯著降低LDL-C和non-HDL-C,並能降低與心血管事件相關的炎症標記物GGT和hs-CRP。HTD1801已獲美國FDA授予2項“快速通道資格認定”和1項“孤兒藥資格認定”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.